Clinical trials
Advanced or Metastatic Solid Tumors clinical trials
Below are recruiting advanced or metastatic solid tumors clinical trials, each written for real people, not researchers. We’re tracking 4,769 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07330544RecruitingPhase 2
Study of entinostat with anlotinib or fulvestrant for advanced breast cancer
This trial tests adding entinostat (a drug that may help hormone therapy work better) to anlotinib or fulvestrant for people with HR-positive, HER2-negative advanced breast cancer that has worsened after prior hormone therapy and a CDK4/6 inhibitor. It aims to find a new treatment option for those who cannot use chemotherapy yet.
Zhejiang, HangzhouAges 18 years+ - NCT07330596RecruitingPhase 2
Study of QL1706 plus chemo for lung cancer that got worse after immunotherapy
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
HefeiAges 18–75 - NCT07328945Recruiting
Personalized treatment for non-small cell lung cancer using a tumor model
This trial tests a new way to choose the best treatment for your lung cancer by creating a model of your tumor in the lab. It may help doctors find the most effective therapy for you.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07325630RecruitingPhase 2
Perioperative study of IBI363 for MHC-II-negative advanced stomach cancer
This trial tests a new treatment called IBI363 given before and after surgery for people with a certain type of advanced stomach cancer that lacks the MHC-II marker. The goal is to see if it helps shrink the tumor and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT07325721RecruitingPhase 2
Shorter radiation with a focused boost for high-risk prostate cancer
This trial tests a shorter course of radiation therapy with an extra 'boost' to the most aggressive part of the tumor, combined with hormone therapy, for men with high-risk or locally advanced prostate cancer that has not spread outside the pelvis.
Charleston, South CarolinaAges 18 years+ - NCT06863805Recruiting
Blood markers in advanced thyroid cancer
This study is looking at how certain substances in the blood (called biomarkers) can help doctors understand and treat advanced thyroid cancer. It is for people who are about to start their first systemic therapy (medication that works throughout the body) for advanced thyroid cancer, and who have already had a genetic test on their tumor.
BolognaAges 18 years+ - NCT07322094RecruitingPhase 1/Phase 2
Study of TORL-1-23 plus chemo before surgery for advanced ovarian cancer
This trial tests a new drug, TORL-1-23, given with chemotherapy before surgery for women with advanced ovarian cancer. It aims to see if this combination is safe and effective in shrinking tumors before they are removed.
Fullerton, CaliforniaAges 18–75 - NCT07318558RecruitingPhase 3
Study of Sac-TMT for advanced ovarian cancer without HRD
This trial is testing a new drug called Sac-TMT for people with advanced ovarian cancer that has not responded well to initial platinum-based chemotherapy and does not have a specific gene change called HRD. It aims to see if this drug can work better than standard treatment.
Birmingham, AlabamaAges 18 years+ - NCT07315750RecruitingPhase 3
Study of three drugs vs standard care for HER2-high stomach cancer
This trial tests a new combination of drugs (Disitamab Vedotin, Trastuzumab, and Tislelizumab) against standard chemotherapy plus Trastuzumab (with or without Pembrolizumab) for people with advanced or metastatic stomach or gastroesophageal junction cancer that has high levels of HER2. The goal is to see if the new combination works better.
Beijing, BJ-BeijingAges 18–75 - NCT07321015RecruitingPhase 2
Fluzoparib after platinum for advanced triple-negative breast cancer
This trial tests the PARP inhibitor fluzoparib as a maintenance treatment for women with advanced triple-negative breast cancer whose disease responded or stabilized after platinum-based chemotherapy. The goal is to see if taking fluzoparib daily can delay cancer growth.
TianjinAges 18–75 - NCT07317414RecruitingPhase 2
Beta-alanine for advanced liver cancer
This trial tests whether beta-alanine, a natural supplement, can help people with advanced liver cancer that cannot be removed by surgery. It aims to see if the treatment can slow tumor growth and improve outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT07317193Recruiting
Genetic causes of adult bile duct disease
This study looks for new genes that might cause abnormal liver test results or specific bile duct diseases in adults, when standard testing hasn't found a clear cause. It also uses healthy blood donors as a comparison group.
Milan, MilanoAges 18–65 - NCT07324785Recruiting
Link between sugar substances and stomach problems in diabetes
This study looks at how sugar-related substances (called advanced glycation end products) might affect stomach muscle function in people with diabetes who have gastroparesis (slow stomach emptying). It compares them to people without diabetes to better understand the link.
Yangzhou, JiangsuAges 18–75 - NCT07323368Recruiting
Perfusion-guided stroke treatment for medium artery blockages
This trial tests a new way to treat strokes caused by blockages in medium-sized brain arteries within 24 hours of symptom onset. It uses brain imaging to select patients who might benefit from a procedure to remove the clot.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05741073Recruiting
Study of European registry data for advanced skin cancers
This study uses information from a European registry to learn how real-world treatments work for advanced non-melanoma skin cancers. It may help doctors improve care in the future, especially for people who have had surgery and radiation or who cannot have curative treatments.
BrusselsAges 18 years+ - NCT06617416RecruitingPhase 3
AK104 for locally advanced lung cancer after chemoradiotherapy
This trial tests a new immunotherapy drug, AK104, for people with stage III non-small cell lung cancer that cannot be removed with surgery. It is for those who have finished chemoradiotherapy and have not gotten worse.
JinanAges 18 years+ - NCT07308990Recruiting
Comparing limited vs. full lymph node removal during prostate surgery
This trial compares two types of lymph node removal during prostate cancer surgery to see if removing fewer lymph nodes is just as effective. It is for men with prostate cancer that has not spread beyond the pelvis.
Lyasny, Minsk OblastAges 18 years+ - NCT07312136Enrolling by invitation
Liver health follow-up study for type 2 diabetes
This study follows up on people with type 2 diabetes who already took part in an earlier study about liver health. It uses an MRI scan to check the liver for fat and other changes, helping doctors understand the long-term impact of metabolic dysfunction-associated steatotic liver disease (MASLD).
Linköping, Östergötland CountyAges 18 years+ - NCT07311876Recruiting
Robotic surgery for head and neck lymphedema
This trial tests a new robotic-assisted surgery to reconnect tiny lymph vessels in people with head and neck swelling. It may help reduce the swelling and improve daily life.
KielAges 22 years+ - NCT07310173RecruitingPhase 2
Study of AST-3424 for advanced liver cancer with high AKR1C3
This trial tests a new drug called AST-3424 in people with advanced liver cancer that has gotten worse after prior treatment. It is for those whose tumor cells have high levels of a protein called AKR1C3, which the drug targets.
Nanjing, JiangsuAges 18–75 - NCT07315113RecruitingPhase 1
Study of NXP900 plus osimertinib for EGFR lung cancer
This trial tests a new study drug called NXP900 combined with the targeted therapy osimertinib for people with advanced EGFR-mutated lung cancer who have already been treated with osimertinib. The goal is to see if the combination can help shrink tumors or slow cancer growth.
Calverton, MarylandAges 18 years+ - NCT06698757RecruitingPhase 2
Testing different cycles of sintilimab before surgery for colorectal cancer
This trial tests how many cycles of the immunotherapy drug sintilimab given before surgery help treat colorectal cancer that is mismatch repair deficient (dMMR) or microsatellite instability-high (MSI-H). It is for locally advanced cancer that has not spread to other parts of the body.
Zheng'zhou, HenanAges 18–75 - NCT07307456RecruitingPhase 2
Toripalimab and BCG for high-risk bladder cancer
This trial tests a combination of two treatments after bladder tumor surgery: a drug called toripalimab (given through a vein) plus BCG therapy (given into the bladder) for people with high-risk non-muscle-invasive bladder cancer. The goal is to see if this combination can help prevent the cancer from coming back.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07312422RecruitingPhase 1/Phase 2
Low-dose radiation with immunotherapy and standard therapy for advanced pancreatic cancer
This trial combines low-dose radiation with an immunotherapy drug (pucotenlimab) and standard treatment for advanced pancreatic cancer. It aims to see if this triple therapy can help control the cancer without using a PD-1/PD-L1 inhibitor before.
Hangzhou, ZhejiangAges 18–75
Hear when a new Advanced or Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for advanced or metastatic solid tumors?
- Yes. Clin2 currently lists 4,769 recruiting advanced or metastatic solid tumors studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a advanced or metastatic solid tumors trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a advanced or metastatic solid tumors trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced or Metastatic Solid Tumors
- Advanced/Metastatic Solid Tumors
- Locally Advanced (Unresectable) or Metastatic Solid Tumors
- Locally Advanced/Metastatic Solid Tumors
- Patients With Advanced Solid Tumors
- Mesothelin-positive Advanced Malignant Solid Tumors
- Recurrent or Metastatic Solid Tumors
- Advanced Solid Tumor
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.